Join the Bavencio group to help and get support from people like you.
Bavencio News
T-Cell Tolerant Fraction Can Predict Immunotherapy Toxicity
MONDAY, Aug. 21, 2023 – The T-cell tolerant fraction predicts clinically significant immune-related adverse events (irAEs) among patients with cancer treated with immune checkpoint inhibitors...
FDA Approves Bavencio as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Rockland, MA and New York, US, JUNE 30, 2020 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the U...
FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
Darmstadt, Germany and New York, US, May 14, 2019 – Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today ...
FDA Grants Accelerated Approval to Bavencio (avelumab) for Urothelial Carcinoma
May 9, 2017 – The U.S. Food and Drug Administration granted accelerated approval to avelumab (Bavencio, EMD Serono, Inc.) for patients with locally advanced or metastatic urothelial carcinoma whose...
FDA Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
March 23, 2017 – The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic...
Ask a question
To post your own question to this support group, sign in or create an account.